Global Women’s Health Drugs Market to 2024 – Influx of New Products Including Orilissa, Relugolix and Bremelanotide

Global Women’s Health Drugs Market to 2024 Research Report provides Key Marketed Products, Pipeline Landscape Assessment, Company Analysis and Positioning, Revenue and Market Share and Strategic Consolidations.

Pune, India - February 12, 2019 /MarketersMedia/ —

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many of these disorders are highly prevalent among the female population.

The Women’s Health Market is relatively small considering the high prevalence of many women’s health indications. However, robust growth is projected over the forecast period due to the influx of a number of new products.

This report covers all indications within women’s health with a particular focus on five key indications: endometriosis, polycystic ovarian syndrome (PCOS), cervical intraepithelial neoplasia (CIN), menopausal disorders and infertility.

*Company Analysis and Positioning:
Revenue and Market Share Analysis by Company
1 Bayer AG - Company to Remain a Market Leader within Women’s Health
2 AbbVie Inc - Orilissa to Reach Blockbuster Status, Boosting Company’s Market Share
3 Allergan - Revenue Gains From Fibristal, Lo Loestrin Fe and Liletta to Offset Losses from Minastrin 24 Fe and Estrace
4 Merck & Co. - Company to Remain a Key Player Due to Growth of Gardasil/Gardasil 9
5 GlaxoSmithKline - Cervarix and Retosiban to Drive Strong Growth
6 Pfizer - How will patent expiration affect revenues for women’s health market?
7 TherapeuticsMD – Women’s Health Specialist to Gain Considerable Market Share by 2024

Get Discount on Global Women’s Health Drugs Market Research Report at https://www.reportsnreports.com/contacts/discount.aspx?name=1854865

Scope
- There are 277 pipeline products in active development for women’s health disorders. Which molecule types and molecular targets are most prominent within the pipeline?
- Merck&Co and Bayer currently represent leading companies within women’s health. Will they maintain this dominance over the forecast period?
- Gardasil, Mirena and Nuvaring and are among the most lucrative drugs within the women’s health market. Which of these will experience a considerable decline in revenue over the forecast period following loss of patent protection?
- The influx of a number of recent market entrants and late-stage pipeline products will have a considerable impact on the women’s health market over the forecast period. Which of these drugs are projected to achieve blockbuster status by 2024?
- In total, 246 licensing deals relating to women’s health products have been completed since 2006. Which types of assets attracted the largest deal values?

Direct Purchase of this Research Report at https://www.reportsnreports.com/purchase.aspx?name=1854865

Reasons to buy:
- Understand the current treatment landscape, with portfolios of key marketed products and a focus on historical and forecast sales patterns, and an overview of each drug’s mechanism of action.
- Analyze the women’s health pipeline through a comprehensive review of the pipeline segmented by stage of development, molecule type and molecular target.
- Consider market opportunities and potential risks by examining trends in clinical trial duration and size, as well as clinical trial failure rates.
- Predict growth in market size by examining multi-scenario forecasting trends from 2017 to 2024 and determine the contributions that different products and companies will make to this growth.
- Identify commercial opportunities in the women’s health deals landscape by analyzing trends in licensing and co-development deals.

Contact Info:
Name: Vishal Kalra
Email: Send Email
Organization: ReportsnReports
Website: https://www.reportsnreports.com/reports/1854865-global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide-to-diversify-landscape-and-drive-growth.html

Source URL: https://marketersmedia.com/global-womens-health-drugs-market-to-2024-influx-of-new-products-including-orilissa-relugolix-and-bremelanotide/481772

Source: MarketersMedia

Release ID: 481772

Latest News

Nissan ex-boss Ghosn's new lawyer questions handling of case

Feb 20, 2019

TOKYO — The newly appointed star defender for former Nissan chairman Carlos Ghosn said Wednesday that he believes the case against his client does "not meet international standards" and could scare international businesses away from Japan. Junichiro Hironaka, who was appointed part of Ghosn's defense team last week, also said he believes his trial might not get underway until after the summer. That could mean months more of detention for the Brazilian-born French auto-industry veteran, who has twice sought and failed to gain release on bail after his Nov. 19 arrest. Hironaka said his gut feeling is that Ghosn, the...

Unlike men's World Cup, no open vote on women's event host

Feb 20, 2019

LONDON — FIFA will still decide the host of the Women's World Cup in secret, unlike the new open vote held last year for host of the 2026 men's tournament. The 2023 Women's World Cup bidding process was launched Tuesday, and FIFA adopted many of the rigorous checks and scrutiny that prospective men's hosts now have to go through. But the final decision is a very different process. Following corruption investigations into the vote for men's hosts in 2018 and 2022, FIFA removed the decision from its ruling committee and gave it to all member associations. When it came to...

Japan trade deficit highest in 5 yrs, hit by China doldrums

Feb 20, 2019

TOKYO — Japan reports its exports tumbled 8.4 percent in January from a year earlier, as slowing Chinese growth pushed its monthly trade deficit to the highest level in nearly five years. Exports to all of Asia dropped 13 percent year-on-year, largely due to the 17 percent plunge in shipments to China, where growth recently has fallen to its slowest pace in three decades. The politically delicate trade surplus with the United States rose 5 percent to $3.3 billion, as exports climbed nearly 7 percent helped by rising shipments of cars and power generating machinery. But imports of American goods...

UK expands no-fly zone for drones around airports

Feb 20, 2019

LONDON — The no-fly zone for drones around British airports is being extended to 5 kilometers (3.1 miles) in an attempt to avert disruptions like the December groundings of flights at Gatwick Airport, officials said Wednesday. The Department for Transport said the zone will widen on March 13 from the current 1 kilometer (0.6 miles). Officials are also working on new legislation to give police more powers to stop and search people suspected of using drones maliciously. Transport Secretary Chris Grayling said people who fly drones near airports "are not only acting irresponsibly, but criminally, and could face imprisonment." More...

Twitter tightens up EU political ad rules ahead of election

Feb 20, 2019

LONDON — Twitter said Tuesday it is tightening up rules for European Union political ads ahead of bloc-wide elections this spring, following similar moves by fellow tech giants Facebook and Google. The social media company said it is extending restrictions already in place for federal elections in the United States. Under the new rules, which will also apply in Australia and India, political advertisers will need to be certified. It's also taking steps to increase transparency. Ads, in the form of "promoted tweets," from the past seven days will be stored in a publicly accessible database showing how much was...

About Us

Frontal Report is an emerging leader in all forms of media. We aim to be the leading news brand for readers around the world.

Contact us: sales[at]frontalreport.com

Subscribe Now!